AKI is an uncommon complication of checkpoint inhibitor immunotherapy. Initial studies estimated the incidence of any-grade AKI to be 1%-2% in patients treated with a single-agent ICPi and 4.5% in those treated with anti–CTLA-4 and anti–PD-1 combination therapy.

Feb 18, 2025 · Although AKI has been reported to have a negative impact on renal outcomes in several diseases, the impact of perioperative AKI on major adverse kidney events (MAKE) in patients who undergo RC remains unclear.

However, the combination of cytotoxic T lymphocyte antigen-4 and PD-1 inhibitors, used to induce a more durable response in cancers such as non–small cell lung cancer, melanoma, or renal cell carcinoma, carries a higher risk of ICI-induced AKI (∼5%) due to the blockade of 2 different checkpoint pathways. 6, 10, 11, 12 The most recently ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment since their introduction ∼15 years ago. However, these monoclonal antibodies are associated with immune-related adverse events that can also affect the kidney, resulting in acute kidney injury (AKI), which is most commonly due to acute tubulointerstitial nephritis (ATIN).

Jan 28, 2023 · ASCO guidelines recommend treating patients empirically with steroids when suspicion of ICI-related AKI is high and no other obvious causes of AKI have been found. Kidney biopsy should be considered only if the AKI is refractory to …

May 31, 2023 · Defective or delayed clearance of MTX may lead to toxicities, especially acute kidney injury (AKI) in 2-13% of patients. We developed a protocol to mitigate side effects by checking MTX levels every 24 hours, administering leucovorin or glucarpidase rescue, and hydration with urine alkalization.

Background: HDMTX AKI delays MTX excretion and increases the risk for severe systemic toxicity. MTX is thought to crystalize in renal tubules at urine [MTX] above the solubility limit, leading to AKI.

We examined outcomes (hemodialysis, mechanical ventilation, ICU admission and death) in cancer patients with normal estimated glomerular filtration rate (eGFR) treated in a tertiary referral center with COVID-19 infection, who developed AKI within 30 days of diagnosis.

In this study we utilize the National Inpatient Sample (NIS) to understand the effect of acute kidney injury (AKI) on inpatient mortality in multiple myeloma patients. Methods: This is a retrospective study utilizing the data obtained from the NIS for the year 2018.

Jan 10, 2019 · The primary outcome measure was hospitalization with AKI or acute dialysis. AKI Incidence and Risk Factors. Among 163,071 patients initiating systemic therapy, 10,880 experienced AKI. The rate of AKI was 27 cases per 1,000 person-years, with an overall cumulative incidence of 9.3%.